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We have shown previously that phenylbutazone and sulfinpyrazone inhibit 
the response of platelets to particulate matter and surfaces, and that this is 
associated with impairment of hemostasis and prolongation of platelet survival 
(2,  3).  Since the pyrazole compounds have  anti-inflammatory properties,  it 
seemed possible that other anti-inflammatory compounds might  have  similar 
effects on platelets. 
Acetylsalicylic  acid  (aspirin)  is  associated  with  hemorrhagic  episodes  in 
man.  Beaumont  and  Willie  (4)  found  that  it  caused  a  prolongation of  the 
bleeding time in adults with cardiac diseases. Recently it has been shown that 
the administration of acetylsaUcylic acid to subjects with hemorrhagic disorders 
also causes a considerable prolongation of the bleeding time (5), and Gast (6) 
has reported that it caused a decrease in platelet-stickiness. Bounameaux and 
van  Cauwenberge  (7)  demonstrated  in  rats  that  administration  of  sodium 
salicylate  also  decreased platelet  adherence to  glass.  Weiss  and Aledort  (8) 
have reported that aspirin inhibits collagen-induced platelet aggregation, and 
we have shown that inhibition of the platelet-collagen reaction impairs hemo- 
stasis (3). In this paper some effects of acetylsalicylic acid on platelet function 
in vitro and in vivo are described. 
Materials and Methods 
Tyrode's Solutions.--Tyrode's solution was prepared as specified by Parker (9). Modified 
Tyrode's solution (containing  no calcium or magnesium), Tyrode-albumin  solution, Tyrode- 
albumin-EDTA, and  Tyrode-gelatin solution, were prepared as previously described (3). 
AcetylsalivyUc Acid (ASA).--(Fisher Scientific  Co., Toronto, Ont.) was dissolved in modi- 
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fled Tyrode's solution and the pH adjusted to 7.35 with sodium hydroxide. This preparation 
was used in the in vitro experiments and was also sometimes given  intravenously. Acetyl- 
salicylic acid (aspirin, Bayer Company, Ltd., Aurora, Ont.) was used as the oral preparation 
in the other in vivo studies. 
Sodium Salicylate.--(Fisher  Scientific Co.) was dissolved in modified Tyrode's solution and 
the pH  adjusted to 7.35  with hydrochloric acid. 
Adenosine  Diphosphate  (ADP)  and  Monophosphate  (AMP).--These  phosphates  (Sigma 
Chemical Co., St. Louis, Mo.) were dissolved in modified Tyrode's solution to  the required 
concentrations. 
Collagen Suspension.--2  g of commercial collagen (Sigma Chemical Co.) were suspended in 
100 ml of modified Tyrode's solution at 0°C and homogenized in a Waring blender for a total of 
5 min. The mixture was centrifuged at 810 g for 15 rain to remove coarse particulate  matter. 
The supernatant suspension was then diluted with modified Tyrode's solution to a concentra- 
tion which would produce maximum aggregation of the platelets being tested, but on further 
dilution would cause less than maxim  .ran aggregation. 
Antlgen-Antibody  Complexes.--Antigen-antibody  complexes were prepared  (10). The con- 
centration used to reduce platelet aggregation was adjusted by dilution with modified Tyrode's 
solution, as with the collagen suspension (see above). 
Polystyrene Coated with Gamma Globulin.--This  suspension was prepared from a 30% poly- 
styrene latex suspension (British Drug Houses, Toronto, Ontario) and a human gamma globu. 
lin solution (Connaught Medical Research Laboratories, Toronto, Ontario) as reported earlier 
(3). The coated polystyrene particles were suspended in modified Tyrode's solution at a  con- 
centration Of 0.1%. The concentration used to induce platelet aggregation was adjusted by 
dilution with modified Tyrode's solution, as with the collagen suspension. 
Thrombin.--Crude  bovine thrombin (Parke Davis  & Co.,  Detroit, Mich.) was dissolved 
in modified Tyrode's solution to the required concentration. 
Animals.--Pigs and rabbits were lightly anesthetized with pentobarbital sodium (approxi- 
mately 20 mg/kg) for cannulation of an external jugular vein or carotid artery and, in the case 
of the rabbits, for examination of hemostatic plug formation in the mesentery and for the in 
vivo experiments with an extracorporeal shunt. 
Glassware.--Glassware used to contain platelets was coated with silicone (General Electric 
dry film SC 87 in carbon  tetrachloride). 
Platelet-Rick Plasma (PRP).--Blood was taken through a carotid artery or external jugular 
vein cannula  (Intramedic Polyethylene Tubing, Clay Adams  Inc.,  New  York,  PE  190  for 
rabbits and PE 320 for pigs) into 3.8% trlsodium citrate or 2% EDTA-saline (1 part anticoagu- 
lant to 9 parts of blood) and centrifuged at 77 g for 15 rain at room temperature. The superna- 
tant PRP was removed with silicone-coated Pasteur pipettes. Human blood was taken from a 
forearm vein using a  19 gauge thin-walled needle and a  plastic syringe. 
Platelet Suspensions.--PRP from EDTA blood was centrifuged at 650 g for 15 min at 4°C. 
The platelets were resuspended and washed twice with cold Tyrode-albumin-EDTA, recovered 
each time by centrifugation, and finally resuspended in Tyrode-gehtin solution to a  platelet 
concentration of 500,000-600,000 per mm  3. The platelet suspension was stored in an ice water 
bath. 
Platdets Counts.--These were done on a Coulter counter (11). 
Platelet Aggregation.--This  was studied by the turbidimetrie method (12). 
In Vitro a4C-Serotonin Labeling of Platelets.--The labeled compound used was 5-hydroxy- 
tryptamine-3'-14C-creatinine  sulfate (14C-5-HT) (Radiochemical Centre, Amersham, England). 
14C-5-HT was added to EDTA platelet-rich plasma and allowed to incubate for 30 rain at 37°C. 
The platelet-rich plasma was then centrifuged at 650 g for 15 rain at 4°C. Suspensions of washed 
platelets were prepared as described above for studies of the release of 14C-serotonin. F-VANS~ PACKHAM~ NISHIZAWA~  MUSTARD~ AND  MURPHY  879 
Release of AMP, ADP, and 14C-Serotonin.--i ml of platelet suspension was mixed with 0.1 
ml of a  solution of axzetylsalicylic  acid  (diluted to the desired concentration with modified 
Tyrode's solution). In the control experiments, 0.1 ml of modified Tyrode's solution was sub- 
stituted for the solution of acetylsalicylic acid. In order to induce platelet  aggregation and 
release platelet constituents, 0.1 ml of a suspension either of collagen, antigen-antibody com- 
plexes, gamma globulln--coated polystyrene, or a thrombin solution was added, and the mixture 
was agitated constantly for 10 min at 37°C. The concentrations of ADP and AMP in the plate- 
lets and in the ambient fluid were determined, and the amounts of 14C in the ambient fluid and 
platelets measured by methods reported elsewhere (3, 11). 
Whole Blood Clotting Time; One-Stage Protkrombin  Time; Partial Tkromboptastin  Time.-- 
These studies were carried out with whole blood, or plasma prepared from blood taken into 
citrate, by methods given in detail in eaxlier publications (13,  14). 
Tkrombin  Clotting Time.--Freeze-dried human fibrinogen (Connaught Medical Research 
Laboratories) was dissolved in distilled water (0.5 g/100 ml) and dialyzed against 0.85% NaCI 
for 12 hr at room temperature. The fibrinogen solution was adsorbed with aluminum hydroxide 
(moist gel, British Drug Houses), 1 part AI (OH)3 to 5 parts fibrinogen solution, incubated at 
37°C for 10 rain, centrifuged at 4000 g for  15 rain). To 0.2 ml of the fibrinogen solution was 
added 0.2 ml of ~s/40 CaCI2, 0.1 ml of the ASA solution, and 0.2 ml of the thrombin solution. 
The clotting time of the fibrinogen solution after addition of the thrombin was determined at 
37°C. 
Hemostasis.--The technique for evaluation of hemostasis by cutting small mesenteric vessels 
has been described  (15).  In these experiments, the acetylsalicylic acid was given orally to 
animals starved for 12 hr. The duration of time from the onset of bleeding to its arrest was 
recorded by direct observation of the vessel. The total duration of any renewed bleeding was 
also observed during the 30 rain following transection of the vessel. 
Statistical  Considerations (16).--The studies on hemostasis were done on 72 animals which 
were randomly assigned to 12 groups of 6 each. On each of 4 days, three groups were studied; 
one group acting as controls, one receiving 100 mg/kg of ASA, and one 200 mg/kg. Thus there 
are four possible sources of variation in the results: 
1. There  may be a  variation attributable to  differences  produced  by  treatment  with 
aspirin. This will be referred to as the dosage effect. Since there are three dosage levels, there 
are 3-1 = 2 degrees of freedom associated with it. This source of variation may in turn be 
partitioned into a linear component (which implies a proportionality between prolongation of 
bleeding time and dosage) and a quadratic component (which implies that there is a prolonga- 
tion related to the square of dosage). The complete experiment explores the model 
Yl =  a +  bxi +  cx] +  ei 
where xl is a particular dosage, Yl the bleeding time, ~i a random error and a, b, and c constants. 
If c=0, there is a simple linear relationship; iS c=b=0, effect is quite unrelated to dosage. The 
tests whether e and b are zero are orthogonal, i.e.  statistically independent, and one of the 
degrees of freedom is associated with each. 
2.  There may be variation attributable to difference in days caused by  a  variety of un- 
specified causes. This is denoted by "day effect." With it are associated 4--1=3 degrees of 
freedom. 
3.  While on each day the bleeding time may be affected by dosage, that is in  the above 
equation either b or c or both are non-zero, the values b and c take may vary from day to day. 
This component of variance is designated "interaction." There are (3-- 1) (4-- 1)  =  6 degrees 
of freedom associated with it. A significant interaction would indicate that on some days, the 
drug has more effect than on others. 
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to treatment. This source of variation is termed "error." For each of the 12 groups of 6, one 
parameter (the mean) is estimated and therefore one degree of freedom lost. Thus in all there 
are  12  X  (6-1)  =  60 error degrees of freedom. 
For the purposes of this experiment, the error mean square is created as the irreducible 
component of variation and provides the denominator for all F  tests. However, if the interac- 
tion mean square is significantly greater than the error mean square, principal effects (days 
and dosage) should be tested not against error but against interaction. The resulting F  tests 
will therefore have 6 rather than 60 degrees of freedom associated with their denominators. 
Platelet Survival S~ties on Rabbits.--These were carried out by a  modification (2,  17)  of 
the method of Leeksma and Cohen (18).  Acetylsaiicylic acid-treated rabbits were given the 
drug twice daily in doses ranging from 50-400 mg/kg per day. The control animals received 
placebo tablets. On the 4th day of this regimen, the animals received intravenously diisopropyl- 
(1,3-'£)  phosphorofluoridate  (in  sterile  solution)  (~-I-DFP)  obtained  from  the  Radio- 
chemical Center. The specific activity of the labeled DFP was 2000/~c/mg and each rabbit 
received 50 #c. The dose of labeled DFP was therefore less than 0.01 mg/kg body weight. The 
rabbits were bled daily for 7 days from ear veins into plastic syringes containing 2% EDTA- 
saline. Platelets from each 10 ml blood sample were isolated and their radioactivities measured. 
The platelets were separated  (2),  put  on a  small piece of  taxed aluminum foil, dried,  and 
weighed. The dried platelets were then placed in a counting vial to which 0.25 ml NCS  (Nu- 
clear-Chicago Corp., Des Plaines, Ill.) was added. 12 hours later a toluene-fluor solution (PPO, 
POPOP)  was  added  and  the radioactivity measured in a  liquid scintillation counter.  The 
radioactivity is expressed as cpm/mg dried platelets. The platelet half-life value for each ani- 
mal was calculated by the iterative, nonlinear, unweighted least squares method (19).  Platelet 
turnover (in platelets/mm  s per day) was calculated as: 
0.693  X  average number of platelets per mm  3 
Half-life in days 
Assay of Aeetylsalicylic Acid in Plasma.--This was carried out by the method of Trinder 
(20)  (Extraction of plasma from untreated animals gave a variable blank value between 1 and 3 
mg per 100 ml of plasma.) 
Extracorporeal  Shunts.--The design of the shunt used has been specified in detail (2). In 
these experiments, ASA was given intravenously to rabbits at a  dosage of 200 mg/kg body 
weight over a period of 10 rain. Control animals were given modified Tyrode's solution. Blood 
flow through the extraeorporeal shunts was begun 30 rain after the intravenous infusion and 
continued for 20 rain. 
In these experiments, the bifurcation of the shunt was coated with gamma globulin  (3). 
The bifurcation  was filled with the solution, emptied, and rinsed three times with modified Ty- 
rode's solution prior to its insertion into the shunt. 
A  Note on Transformatiom.--To meet more closely the assumptions underlying analysis of 
variance (principally that the error terms be normally distributed and have a  uniform vari- 
ance), it is sometimes desirable to use not the measurments in their natural state hut to take 
some  mathematical function of  these,  such  as  the  logarithms.  This  procedure,  while  not 
destroying the information in the values, modifies it somewhat. It should be regarded as a 
simple computational device which may or may not have an interpretable biological meaning. 
It is convenient in expressing means or confidence limits to convert them back to the original 
system of measurement. 
RESULTS 
In Vitro  St~ies.--The addition  of acetylsalicylic  acid  (ASA) to citrated 
human PRP suppressed  platelet  aggregation  induced by collagen  but did not EVANS~ PACKHAM~ NISHIZAWA, MUSTARD, AND MURPHY  881 
influence aggregation induced by ADP (Fig. 1). Similar results were observed 
with pig and rabbit PRP. Shown in Fig. 2 is the effect of different concentra- 
tions of ASA on platelet aggregation induced by collagen. Acetylsalicylic acid 
also  inhibited  thrombin-induced  platelet  aggregation in  human  and  rabbit 
citrated PRP (Fig. 3).  This effect was demonstrable only with the minimum 
doses required to produce platelet aggregation. Because the high concentration 
of  thrombin  necessary  to  induce  platelet  aggregation  in  citrated  pig  PRP 
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Fro. 1. Platelet aggregation  in citrated platelet-rich human plasma (PRP) induced by the 
addition of a collagen  suspension or ADP (final concentration 5 X 10  -7 ~).  Increased light 
transmission indicates platelet aggregation.  The recordings on the left show the response of 
the platdets without the addition of ASA; on the right, the response of the platdets in the 
presence of ASA (final concentration 1 mg/ml). Only collagen-induced aggregation was 
suppressed. 
caused the rapid onset of fibrin formation, it was not possible to study the effect 
of acetylsalicylic acid on thrombin-induced platelet aggregation in pig plasma. 
To examine the influence of this drug in a  system in which  the effects of 
antigen-antibody complexes  and  gamma  globulin-coated  surfaces  could  be 
explored,  we  used  suspensions  of  washed  human,  pig,  or  rabbit  platelets. 
Acetylsalicylic acid inhibited the  action of collagen,  antigen-antibody com- 
plexes,  and gamma globulin-coated polystyrene in inducing platelet aggrega- 
tion in these suspensions (Fig. 4). In the washed platelet suspension, the effect 
of thrombin in low concentrations was also inhibited by acetylsalicylic acid 
(Fig. 5). However, although ASA inhibited thrombin-induced platelet aggrega- 
tion, it did not inhibit the clotting of fibrinogen by thrombin (Table I). 882  ACETYLSALICYLIC  ACID AND PLATELET FUNCTION 
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Fzo. 2. Effect of ASA on collagen-induced platelet aggregation in citrated platclet-rich pig 
plasma. Final concentrations of ASA; A, 0; B, 0.1 mg/ml; C, 0.5 mg/ml; D, 1 mg/ml. 
It  is  known  that  thrombin,  collagen,  antigen-antibody  complexes,  and 
gamma globulin-coated surfaces cause the release of platelet constituents such 
as serotonin, ADP, and AMP into the ambient fluid. Accordingly, we examined 
the  effect of ASA on the  release of these  compounds from pig platelets.  The 
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Fro. 3. Effect of ASA (final concentration  1 mg/ml) on thrombin-induced platelet aggrega- 
tion in citrated  platelet-rich  rabbit plasma  (PRP) EVANS~ PAC~  NISHIZAWA~ MUSTAILD~ AND  MIYR~HY  883 
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FIG. 4.  Effect of ASA (final concentration 1 mg/ml) on platelet aggregation in a suspension 
of washed human platelets. Aggregation was induced by either a collagen suspension,  antigen- 
antibody complexes (AgAb), or polystyrene particles coated with gamma globulin (G-GLOB. 
POLYSTY.) ASA suppressed the response of the platelets to all these stimuli. 
addition of ASA to a platelet suspension reduced the amount of ADP and AMP 
released by a  collagen suspension  (Table  II). 
Pig platelets were labeled  in  vitro with 14C-serotonin. In the presence  of 
ASA, they released  less radioactivity into the ambient fluid when they were 
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Fro. 5.  Effect of ASA (final concentration 1 mg/ml) on thTombin-induced platelet aggrega- 
tion in a suspension  of washed human p]atelets. Final concentration of thrombin, 0.1 units/m]. 884  ACETYLSALICYLIC  ACID AND PLATELET FUNCTION 
stimulated  with  collagen,  antigen-antibody  complexes,  or  gamma  globulin- 
coated polystyrene (Table III). The effect of low concentrations of thrombin 
on the release of platelet constituents from a suspension of washed pig platelets 
was inhibited by acetylsalicylic acid (Table IV). 
TABLE I 
The Effect  of Acaylsalicylic  Acid on the Clotting of Fibrinogen by Thrombin 
Experiments  Thrombin, final  Acetylsalicylicacid,  final  Clottlngof  fibrinogentlme 
concentration  concentration  solution 
1 
un,  i~s/mt 
0.6 
0.6 
0.6 
1.4 
1.4 
1.4 
0.14 
0.14 
0.29 
0.29 
1.4 
1.4 
~/mZ 
0 
140 
64O 
0 
140 
64O 
0 
646 
0 
640 
0 
640 
$8C 
35 
34 
36 
24 
23 
24 
62 
65 
35 
36 
22 
24 
TABLE II 
E.~ea of Ace3ylsaHcylic Acid on Collagen-Induced Rdeas¢ of Platelet ADP and AMP 
Material added to platelet suspension 
Collagen suspension 
Tyrode's solution 
Final  concen- 
tration of 
acetylsaH- 
cylic acid in 
platelet sus- 
pension 
~g/ng 
0 
1 
10 
50 
Platelet ADP and AMP 
after release reaction 
ADP  AMP 
ADP and AMP in ambient 
fluid  after  release reaction 
50 
61 
76 
78 
86 
nanomol,s/ng of platela suspension 
13  64 
17  56 
15  56 
14  44 
15  26 
23 
20 
20 
17 
Sodium salicylate  was also found to suppress  platelet  aggregation induced 
by  collagen  and  low  concentrations  of  thrombin  but  did  not  affect  ADP- 
induced platelet aggregation in citrated PRP. The addition of sodium salicylate 
to  a  suspension  of  washed  14C-serotonln-labeled  pig  platelets  inhibited  the 
release of radioactivity  and nucleofides induced by collagen, antigen-antibody 
complexes,  and gamma globulin-coated polystyrene  (Table V). EVANS~ PACKHAM, NISHIZAWA~  MUSTARD~ AND MURPHY  885 
In  Vivo Studies.--Four  aspects of the in vivo effects of acetylsalicylic acid 
were studied in rabbits: the suppression of collagen-induced platelet aggregation 
following oral administration of the drug, the effects of oral administration on 
hemostasis, the effect of the drug on platelet survival, and the effect of intra- 
TABLE III 
Effect of Acetylsalicylic Acid on the Rdeoze of Radioactivity, ADP, and AMP from x4C-Sero- 
tonin-Labded  Platdets Exposed to Collagen, Antigen-Antibody  Complexes or Gamma 
Globulin-Coated Polystyrene 
Material added to platelet suspension 
Experiment I 
Collagen suspension 
~t  tc 
Tyrode's solution 
14  gl 
Experiment II 
Antigen-antibody complexes 
Tyrode's solution 
Experiment III 
Gamma globulin-coated polystyrene 
Tyrode's solution 
Final concen- 
tration of 
acetylsalicylic 
acid in platelet 
Suspension 
t,  glr,  tl 
m 
10 
100 
i0 
100 
D 
10 
100 
10 
100 
10 
100 
10 
100 
Ambient 
fluid 
26,675 
18,787 
14,014 
10,440 
8,198 
8,621 
37,852 
23,415 
2,916 
721 
2,199 
1,329 
7,898 
3,798 
2,762 
1,642 
1,886 
2,242 
14C 
Plstelets 
cpm/mg 
13,450 
13,650 
16,800 
16,080 
16,800 
16,660 
7,780 
8,220 
19,400 
20,300 
18,800 
21,400 
11,150 
16,700 
14,520 
19,290 
17,000 
16,480 
ADP and AMP 
in ambient fluid 
after release 
reaction 
ADP  AMP 
nanomoles/  ml 
14  14 
11  12 
8  10 
10  7 
10  5 
8  7 
22  19 
19  14 
8  5 
6  2 
6  2 
5  2 
10  7 
6  8 
6  5 
7  3 
5  4 
5  3 
venous administration of the drug on the formation of deposits in the bifurca- 
tion of an  extracorporeal shunt. 
The effect of in vivo administration  of acetylsalicylic acid: Platelet aggregation 
in vitro in citrated PRP prepared from blood taken from rabbits before and 30 
rain after the intravenous infusion of ASA (200 mg/kg) was similar to that seen 
in the in vitro experiments.  The response of the platelets in citrated platelet- 
rich plasma to collagen and thrombin, but not to ADP, was suppressed after 
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Collagen-induced platelet aggregation was studied 2 hr after the oral admin- 
istration of ASA to rabbits at different dosage levels (100 mg/kg of ASA pro- 
duced a plasma level of 38 rag/100 ml). Aggregation induced by this stimulus 
was inhibited (Table VI). In these experiments, the oral administration of ASA 
had no detectable effect on the platelet count, the whole blood-clotting time in 
glass and silicone-coated tubes, the one-stage prothrombin time, or the partial 
thromboplastin time (Table VII). 
TABLE IV 
Effect of Acetylsalic  'lic .~ dd on Thrombin-induced  Rdease of Platdet Constituents 
Material added.to platelet 
$uspenslon~ 
Thrombin 1 unit/ml 
Thrombin 0.2 units/ml 
Tyrode's solution 
Final concen- 
tration of 
acetylsalicylic 
acid inplatelet 
suspension  Ambient fluid  Platelets 
ADP and AMP in 
ambient fluid after 
release reaction 
~g/ml 
0 
10 
50 
100 
0 
10 
50 
100 
0 
10 
50 
100 
1.C 
~pm/m2 
110,941 
97,390 
91,573 
88,718 
35,228 
35,228 
18,877 
8,847 
6,089 
5,712 
5,854 
6,644 
cm/mg 
3,970 
5,870 
5,620 
5,880 
16,800 
17,000 
23,100 
28,000 
27,200 
27,900 
24,700 
24,800 
ADP  I  AMP 
n.a~emoles/ml 
37  29 
31  30 
25  19 
21  19 
19  15 
12  14 
15  21 
9  7 
6  5 
6  5 
6  5 
2  5 
* 0.1 ml added to 1.1 ml of platelet suspension containing acetylsalicylic  acid. 
The effect on hemostasis:  Acetylsallcylic acid was given orally to rabbits in the 
dosage of 100 or 200 mg/kg. It can be seen (Table VIII and IX)  that, upon 
transection of the  mesenteric vessels  2  hr  after administration  of the  drug, 
hemostasis was impaired. The rabbits given ASA showed a considerable length- 
ening of the time taken for the formation of a platelet plug capable of arresting 
hemorrhage.  There was  considerable  renewed  bleeding  through  the  platelet 
plugs indicating that they were unstable. The total time of bleeding represents 
the combined time for primary arrest and the duration of the renewed bleeding. 
In comparison, control animals showed little renewed hemorrhage through the 
plugs and the total time of bleeding rarely exceeded 5 min. The extent of the 
prolongation is dose dependent. Over the dosage range used in these experi- 
ments, the relationship appears to be linear. No significant quadratic component 
was demonstrated. While the effect was consistent in the few days of study, the 
regression slope of prolongation on dosage varied appreciably from day to day. EVANS~  PACKHAM~  NISHIZAWA~  MUSTARD~  AND  MURPHY  887 
TABLE V 
Effect  of Sodium  Salicylate  on  the Release  of Radioactivity,  ADP, and  AMP from  14C-Sero- 
tonin-labeled  Pig Platelets Exposed  to Collagen, Antigen-Antibody  Complexes or 
Gamma Globulin-Coated  Polystyrene 
Material added to platelet  suspension 
Collagen suspension 
Antigen-antib~ly  complexes 
Gamma globulin-coated polystyrene 
Tyrode's solution,, 
t 
c¢  t- 
tra  of 
sal  t¢ 
in platelet 
suspension 
~,g/t,g 
0 
10 
100 
0 
10 
lO0 
0 
10 
IO0 
0 
10 
100 
t4C 
ADP and AMP 
in ambient fluid 
after release 
reaction 
Ambient fluid  Platelets  ADP  AMP 
cpm/mg 
13,920 
19,000 
19,500 
6,790 
14,850 
16,500 
3,960 
9,970 
14,600 
15,300 
16,700 
17,480 
cpm/ml 
3,496 
1,277 
789 
29,242 
6,720 
4,984 
34,918 
12,025 
5,602 
902 
869 
583 
nanomoles/rat 
20  11 
17  9 
14  7 
29  24 
24  17 
15  9 
29  14 
25  10 
16  10 
10  3 
3  2 
2  2 
TABLE  VI 
Effect  of Oral Administration*  of Acetylsalioylic  Acid to Rabbits  on the Aggregation  of Their 
Platdets to a Collagen Suspension 
Oral dosage of ASA  Maximum platelet aggregation (Per cent of control)~: 
mg/kg 
0 
50 
100 
200 
300 
100 
95 
76 
20 
0 
* ASA was given 2 hr before the sample of blood was taken for aggregation studies. Ag- 
gregation was measured in citrated PRP. 
~; Maximum light transmission through the PRP during platelet aggregation was assigned 
a value of 100% for the control sample (taken before the administration of ASA). The maxi- 
mum light transmission obtained in the presence of ASA was calculated as a percentage of 
this. These values are dependent on the collagen concentration and represent relative values 
only with a given collagen suspension. The values shown are the means of three experiments. 
This is reflected in the interaction term in the analysis of variance which exceeds 
the error term to a  highly significant extent. Accordingly, as has been noted 
above, the effect of dosage has to be tested against the interaction mean square 
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The effect on platetet survival:  Platelet survival studies were done on rabbits 
receiving, orally, various doses of acetylsalicylic acid  (Table X). Control ani- 
mals were given placebo tablets.  On the 4th day of the regimen the animals 
were injected with aH-DFP, platelets were isolated daily thereafter for 7 days 
and their radioactivity measured. Platelet survival follows a normal distribu- 
tion curve sufficiently closely for accurate analysis (21). In a previous paper (2), 
however, it was noted that the standard deviation of mean survival is sometimes 
proportional to the mean, a relationship which is abolished if the logarithms of 
TABLE  VII 
Effect of Acetylsalicylic  Acid on Platdet Count and Clotting Tests 
Mean values 2 hr after oral  Mean values before adminis-  administration of ASA 
Test*  tration of ASA  (200 mg/kg) 
4.6  Whole blood clotting time, glass, min 
Significance of  difference between mean 
values 
Whole blood clotting time, silicone, rain 
Significance of  difference between mean 
values 
Prothrombin time, sec 
Significance of  difference between mean 
values 
Partial thromboplastin time, sec 
Significance  of  difference  between  mean 
values 
Platelet count, No./mm  s X 108 
Significance of  difference between mean 
values 
4.4 
t  =  0.9 
P  <0.4 
8.8  I  9.1 
t =  0.7 
P<  0.5 
17.0  I  18.3 
t  =  1.42 
P  <0.2 
39.9  !  37.5 
t =  0.74 
P<0.5 
464  I  472 
t  =  0.69 
P  <0.5 
* The values shown are the means from studies in 10 rabbits. 
the values are used. This relationship was evident in the present study and to 
stabilize the variance a logarithmic transformation was used on the individual 
estimates of the means before the regression line on dosage was fitted. In spite 
of some irregularity in results which may be due to the small size of some of the 
treatment groups, there is considerable increase in mean survival with increas- 
ing ASA intake, and this is significant at the 1 in 100  level. There is a  corre- 
sponding decrease in platelet turnover.  Since the variance for this value was 
naturally stable,  no logarithmic transformation was required. 
Formation  of deposits  of blood materials  in  the  bifurcation  of extracorporeal 
shunts: We have reported earlier (22) that by using the logarithms of the weights 
of the deposits, the distribution of the weights is normalized and the variance 
which is ordinarily closely related to the mean is stabilized. All the calculations 
are therefore carried out on the logarithms of the dry weights of deposits but EVANS~ PACKHAM~ NISHIZAWA~ MUSTARD~ AND MURPHY  889 
mean values have been converted back into the original scale  for display in 
Table XI. These values are accordingly geometric means. It can be seen that 
administration of acetylsalicylic acid (200 mg/kg) intravenously 30 min before 
blood flow was started in the shunt produced a  significant diminution in the 
amount of deposit on a bifurcation coated with gamma globulin. There was no 
significant difference in mean rates of flow between the two groups of animals. 
TABLE VIII 
Effect of Oral Administration  of Acetylsalicyli~ Acid on Primary Bleeding Time in Rabbits 
Treatment group 
Study* 
1  2  3  4 
Mean primary  bleedJngtime 
Mean primary 
bleeding  time for 
all groups 
$CC  $~C  $8C  $~C  $$C 
Control  144  270  274  284  243 
lOOmg/kg  315  441  508  402  417 
200mg/kg  320  660  957  930  717 
Analysis  of variance 
Source  Sum ofsquares  F  P 
Days 
Dosage 
Linear 
Quadratic 
Interaction (dosage  X  days) 
Error 
Degrees 
of 
freedom 
3 
21 
61 
60 
1,092,486 
2,757,446 
2,693,269 
64,178 
688,428 
239,200 
Total  .............................  71  4,777,560  [ 
* There were 6 animals in each group for each study. 
3.17 
12.02 
23.47 
0.56 
28.78 
<0.25 
<0.01 
<0.001 
<0.5 
<0.0001 
DISCUSSION 
The results from this study show that ASA inhibits platelet aggregation in 
citrated PRP or in suspensions of washed platelets induced by collagen, antigen- 
antibody  complexes,  or  gamma globulin-coated polystyrene,  but  does  not 
inhibit aggregation induced by ADP. In addition, ASA inhibits platelet aggrega- 
tion induced by small doses of thrombin. There is evidence that thrombin and 
particulate stimuli cause platelet aggregation by releasing ADP from platelets 
(23).  Since  doses  of  ASA  which  inhibited  platelet  aggregation  induced  by 
thrombin or by the particulate stimuli also inhibited the release of platelet con- 
stituents, it seems likely that the effect of ASA on platelet aggregation can be 890  ACETYLSALICYLIC  ACID AND  PLATELET  ]~UNCTION 
attributed to inhibition of the release of platelet ADP. Weiss and Aledort (8) 
have  come to a  similar conclusion concerning the effect of ASA in inhibiting 
collagen-induced platelet aggregation. We originally thought that ASA did not 
influence  thrombin-induced  platelet  aggregation  (1,  24)  but  we  have  sub- 
sequently found that ASA will inhibit thrombin-induced platelet aggregation 
TABLE IX 
Elect of Oral Administration  of Acetylsalicylic  Acid on  Total  Bleeding  Time in  Rabbits 
Treatment 
Study* 
1  2  3  4 
Mean totalbleeding  time 
Mean total 
bleeding time 
for all groups 
sec  $e6  $e6  see  $~6 
211  269  290  288  I  263  Control 
P 
100 mg/kg  987  1163  704  774  i  897 
200mg/kg  1517  1638  1144  1301  1  1391 
Analysis of Variance 
Source  Sum of squares  F  P 
Days 
Dosage 
Linear 
Quadratic 
Interaction (days X  dosage) 
Error 
Degrees of 
Freedom 
3 
2 
1 
1 
6 
6O 
0.3075 
8.6544 
8.3744 
0.2800 
0.2871 
0.1689 
Total  ........................  71  9.4180 
2.14 
90.44 
175.02 
5.85 
16.99 
<0.25 
<0.0001 
<0.0001 
<0.i 
d0.0001 
N.B. To stabilize the variance the transformation Y =  log (X +  600) is used where X is 
the number of seconds. The figures in the analysis of variance refer to this transformation. 
However,  the mean values calculated from  this transformation have been converted back 
into the original scale by the reverse process, i.e., X  =  antilog (Y) -- 600. The mean values 
given above are in this form. 
* There were 6 animals in each group for each study. 
if the concentration of thrombin used is adjusted to that which will just produce 
platelet aggregation. In earlier studies (3), we similarly failed to demonstrate 
an effect of the pyrazole compounds on thrombin-induced platelet aggregation, 
because the concentration of thrombin used was too high (25). 1 
ASA is converted to sodium salicylate in vivo, and our in vitro results indicate 
that sodium salicylate also is effective in inhibiting platelet aggregation induced 
1  Packham, M. A., and J. F. Mustard. Unpublished  observations. EVANS~  PACKHAM~  NISHIZAWA~  MUSTARD,  AND  MURPHY  891 
by the particulate stimuli, probably by the same mechanism of reducing the 
extent  of the release  of  platelet  constituents.  There  is  evidence  from  other 
studies (7, 26) that sodium salicylate decreases platelet stickiness and interferes 
with hemostasis. 
TABLE X 
Effect  of  Oral  Administration  of Acetylsalicylic  Acid  on  Platdet  Economy  in  Rabbits 
Dose per day 
mglkg 
0 
50 
100 
150 
200 
300 
400 
Intercept 
Regression 
t 
P 
No. of animals 
studied 
16 
5 
12 
2 
5 
2 
2 
Mean platelet half-life 
days 
1.33 
3.07 
3.18 
1.40 
4.23 
1.42 
3.89 
0.43579* 
0.0024303* 
2.842 
<0.01 
Mean platelet turnover 
No.~ mm  3 per day  X  10  B 
359 
263 
223 
258 
158 
305 
101 
324.90 
0.58807 
2.804 
<0.01 
* These values refer to the logarithms of the platelet half-life in days. 
TABLE XI 
Effect  of Acetylsalicylic  Acid on the Formation  of Deposits  in Gamma Globulin-Coated 
Bifurcations Connected to Extracor ~oreal Shunts 
Mean flow rate, ml/min 
Significance of difference between means 
Geometric mean dry weight of deposit, mg 
Significance of difference between means 
Untreated rabbits  Rabbits given 200 
(5)  mg/kg of ASA (5) 
117.3  92.8 
t =  1.20 
P<0.3 
22.80  I  6.37 
t  =  7.57 
P  <  0.001 
The results from the in vivo experiments substantiate the in vitro studies. 
The  concentrations  of ASA necessary to inhibit platelet aggregation were of 
the same magnitude as those in the in vitro studies. 
There is considerable evidence (15) that the exposed connective tissue at the 
end of a  transected vessel provides a  stimulus for the formation of a  platelet 
mass.  In  the present experiments,  the administration of ASA in doses which 
inhibited  collagen-induced  platelet  aggregation  caused  defective  hemostasis 892  ACETYLSALICYLIC ACID AND  PLATELET I~UNCTION 
manifested by a delay in the primary arrest of bleeding and by increased sus- 
ceptibility to breakdown of the platelet plug with renewed bleeding through it. 
The action of ASA on hemostasis could be due to its effects on collagen and 
thrombin-induced platelet aggregation. Since in the acute experiments, ASA did 
not affect blood coagulation, and we could show no effect of ASA on the con- 
version of fibrinogen to fibrin by thrombin, it seems reasonable to attribute the 
hemostatic defect to inhibition of platelet aggregation. 
The function of the platelet is important in determining its survival (2, 3, 
25). The results from this study indicate that ASA prolongs platelet survival. 
Since the interaction of platelets with stimuli such as collagen, antigen-antibody 
complexes, or viruses can induce the release of platelet constituents and cause 
aggregation, it is possible that ASA increases platelet survival by suppressing 
the response of platelets to such stimuli. 
In the experiments with the extracorporeal shunts we used surfaces which 
had been exposed to gamma globulin. This provided a surface which, in vitro, 
produced adherence of platelets to the surface and to each other with extensive 
release of ADP  (3).  When the bifurcation is coated with gamma globulin it 
produces more than four times the deposit found in an uncoated bifurcation 
(27). The results of the present experiments show that  ASA  produces a  sig- 
nificant diminution in the amount of material deposited when blood flows past 
such a surface. 
Addendum.--Since  completion  of this manuscript, M. B. Zucker and J. Peterson 
(1968, Proc. Soc.  Exptl.  Biol.  Med.  12"/:547) have reported that acetylsalicylic  acid 
abolishes the secondary aggregation of platelets induced by critical concentrations of 
adenosine diphosphate  (ADP) as well as inhibiting  platelet aggregation  induced by 
connective  tissue particles.  J.  R. O'Brien (1968. Lancet.  1:894) has shown that the 
oral administration of acetylsalicylic acid to human subjects suppressed the secondary 
response of these platelets to adrenaline and ADP as well as inhibiting  the effect of 
collagen. He did not find any effect on thrombin-induced  platelet aggregation. 
SITM:M.ARY 
Acetylsalicylie acid (ASA,  aspirin) and sodium  salicylate inhibit platelet 
aggregation induced by collagen,  antigen-antibody complexes, gamma globulin- 
coated particles  or thrombin. These compounds suppress the release  of platelet 
constituents, such as adenosine diphosphate  (ADP) and serotonin, induced by 
such stimuli. Since ASA  and sodium salicylate  do not inhibit ADP-induced 
platelet  aggregation,  it  appears that  their  effect  on the action  of  the  other  stimuli 
is  due to a decrease in the amount of  ADP  released.  The administration of  ASA 
to rabbits (in doses which inhibited collagen-induced platelet aggregation) 
impaired hemostasis, prolonged platelet  survival, and diminished the amount 
of deposit  formed in an extracorporeal  shunt. ~EVANS~ PACKIIAM~ NISItlZAWA, M'USTARD~ AND MURPttY  893 
BIBLIOGRAPHY 
1.  Evans  G.,  E.  E.  Nishizawa,  M.  A.  Packham,  and  J.  F.  Mustard.  1967.  The 
effect of acetylsalicylic acid (aspirin) on platelet function. Blood. 30:550. 
2.  Mustard, J. F., H. C. Rowsell, H. A. Smythe, A. Senyi, and E. A. Murphy. 1967. 
The effect of sulphinpyrazone on platelet economy and thrombus formation in 
rabbits. Blood. 29:859. 
3.  Packham, M. A., E. S. Warrior, M. F.  Glynn, A. S. Senyi, and J. F. Mustard. 
1967.  Alteration  of  the  response  of platelets  to  surface  stimuli  by pyrazole 
compounds. J. Exptl. Meal. 126:171. 
4.  Beaumont, J. L., and A. Willie. 1955. Influence sur l'h~mostase, de l'hypertension 
art~rielle,  des antivitamines  K,  de l'h~parine et de l'acide ac~tyl salicylique. 
Sang. 26:880. 
5.  Quick,  A. J.  1966.  Salicylates and  bleeding:  the  aspirin  tolerance test.  Am. J. 
Med. Sci. 9.52:265. 
6.  Gast, L. F. 1964. Influence of aspirin on haemostafic parameters. Ann. Rheumatic 
D/seases. 23:500. 
7.  Bounameaux,  Y.,  and  H.  van  Cauwenberge.  1954.  Action  de  la  cortisone,  de 
I'A.C.T.H. et du  salicylate de  soude  sur les  thrombocytes et la  coagulation 
sanguine. Sang. 25:889. 
8.  Weiss, H. J., and L. M. Aledort. 1967. Impaired platelet connective tissue reaction 
in man after aspirin injection. Lancet.  2:495. 
9.  Parker,  R.  C.  1961.  Methods  of Tissue Culture.  Harper and  Row,  New  York. 
3rd edition. 57. 
10.  Movat, H. Z., J. F. Mustard,  N. S. Taichman, and T. Uriuhara.  1965.  Platelet 
aggregation  and  release  of  ADP,  serotonin,  and  histamine  associated  with 
phagocytosis of antigen-antibody complexes. Proc.  Soc. Exptl. Biol. Med. 120: 
232. 
11.  Glynn, M. F., H. Z. Movat, E. A. Murphy,  and J. F. Mustard.  1965.  Study of 
platelet  adherence  and  aggregation  with  latex  particles.  ].  Lab.  Clin.  Med. 
65:179. 
12.  Mustard, J. F., B. I-Iegardt, H. C. Rowsell, and R. L. MacMillan. 1964. Effect of 
adenosine nudeotides  on platelet aggregation and  clotting time. J.  Lab.  Clin. 
Med. 64:548. 
13.  Murphy,  E. A.,  and J.  F.  Mustard.  1960.  Dicumarol  therapy.  Some effects on 
platelets and their relationship to clotting tests. Circulation  Res. 8:1187. 
14.  Mustard, J. F., H.  C. RowseU, F. Lotz, B. Hegardt,  and E. A. Murphy.  1966. 
The effect of adenine  nudeotides  on thrombus formation, platelet  count and 
blood coagulation. Exptl. Mol. Pathol.  15:43. 
15.  I-Iovig, T., H. C. Rowsell, W. J. Dodds, L. Jffrgensen, and J. F. Mustard.  1967. 
Experimental hemostasis in normal dogs and dogs with congenital disorders of 
blood coagulation. Blood. 30:636. 
16.  Cochran, W.  G., and G. M. Cox. 1957. Experimental Designs. John Wiley Inc., 
New York. 2nd edition. 
17.  Murphy, E. A., and J. F. Mustard. 1961. Dicumarol therapy and platelet turnover. 
Circulation  Res. 9:402. 894  ACETYLSALICYLIC  ACID AND PLATELET FUNCTION 
18.  Leeksma,  C. H. W.,  and J.  A.  Cohen.  1966. Determination of the life  span of 
human blood platelets  using labelled  di-isopropyl-fluorophosphonate. J.  Clin. 
Invest. 35:964. 
19.  Rao,  C.  R.  1952.  Advanced  Statistical  Methods  in  Biometric  Research.  John 
Wiley Inc., New York. 
20.  Trinder, P. 1954. Rapid determination of salicylate in biological fluids.  Biochem. 
J. 57:301. 
21.  Mustard, J. F., H. C. Rowsell,  and E. A. Murphy. 1966. Platelet economy (plate- 
let survival and turnover). Brit. J. Haematol. 12:1. 
22.  Mustard, J. F., E. A. Murphy, H. C. Rowsell,  and H. G. Downie. 1962. Factors 
influencing thrombus formation in vivo. Am. J. Med. 33:621. 
23.  Mustard, J. F., M. F. Glynn, E. E. Nishizawa, and M. A. Packham. 1967. Platelet 
surface  interactions:  relationship  to  thrombosis  and  hemostasis.  Federation 
Proc. 26:106. 
24.  Evans,  G.,  M.  A.  Packham,  and  J.  F.  Mustard.  1967.  Spontaneous bruising. 
Lancet. 2:724. 
25.  Packham, M. A., E.  E. Nishizawa,  and J.  F.  Mustard.  1968.  The response of 
platelets to tissue injury. Biochem. Pharmacol. Suppl.  171. 
26.  Hofmann,  H.  1956.  Experimentelle  Untersuchungen  zur  Frage  der  Blutungs- 
zeitver~nderung durch Salizylate. Med. Monatsschr. 10:84. 
27.  Evans,  G.,  and J.  F. Mustard.  1968. Platelet-sufface  reaction  and  thrombosis. 
Surgery. 64:273. 